Thurston Springer Miller Herd & Titak Inc. Has $3.03 Million Position in Amgen Inc. (NASDAQ:AMGN)

Thurston Springer Miller Herd & Titak Inc. grew its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 28.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,725 shares of the medical research company's stock after purchasing an additional 2,140 shares during the period. Thurston Springer Miller Herd & Titak Inc.'s holdings in Amgen were worth $3,030,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Tallon Kerry Patrick bought a new position in shares of Amgen during the 4th quarter valued at $270,000. Brighton Jones LLC increased its position in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after buying an additional 5,226 shares during the last quarter. Optas LLC raised its holdings in Amgen by 15.6% during the fourth quarter. Optas LLC now owns 1,180 shares of the medical research company's stock valued at $308,000 after buying an additional 159 shares in the last quarter. Calamos Wealth Management LLC raised its holdings in Amgen by 2.2% during the fourth quarter. Calamos Wealth Management LLC now owns 2,459 shares of the medical research company's stock valued at $641,000 after buying an additional 54 shares in the last quarter. Finally, Sargent Investment Group LLC lifted its position in shares of Amgen by 17.9% in the fourth quarter. Sargent Investment Group LLC now owns 1,243 shares of the medical research company's stock worth $336,000 after buying an additional 189 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN traded up $3.23 on Friday, hitting $290.33. The stock had a trading volume of 1,996,092 shares, compared to its average volume of 2,806,486. The company has a market capitalization of $156.11 billion, a price-to-earnings ratio of 38.45, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The firm's 50 day moving average price is $281.91 and its 200-day moving average price is $285.36. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. During the same period last year, the firm posted $3.96 EPS. The business's revenue was up 9.4% on a year-over-year basis. On average, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on AMGN. Piper Sandler lowered their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. UBS Group restated a "neutral" rating and issued a $315.00 price objective (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Cantor Fitzgerald assumed coverage on shares of Amgen in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 target price on the stock. Finally, Morgan Stanley reissued an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.